

(hypercarbia, tachycardia, raised temperature, hypoxaemia, acidosis, hyperkalaemia<sup>4</sup>), such as sepsis, respiratory failure, or acute kidney injury: these clinical features are also frequently observed in critically ill patients with COVID-19.<sup>5</sup> Also adequate stocks of dantrolene<sup>6</sup> and activated charcoal filters<sup>7</sup> should be available.

Population genome and exome sequencing projects have revealed the high population incidence (1:1500) of genetic variants associated with susceptibility to MH.<sup>8</sup> It is likely that there are genetic and non-genetic factors contributing to the discrepancy between the prevalence of such genetic variants and the incidence of clinical MH,<sup>9</sup> but these are unknown. It is possible that the non-genetic contributors to triggering may be more common in critically ill patients, so although the current low incidence of MH in the ICU setting is likely to reflect the infrequent use of volatile anaesthetic sedation, an increase in this practice may reveal that critically ill MH susceptible patients have a greater chance of triggering than in the operating theatre.

As volatile anaesthetic sedation becomes more prevalent, intensivists and ICU nurses should be added to anaesthetists, pre-hospital practitioners, and emergency room physicians in the list of practitioners who need to be explicitly aware that MH reactions still occur, and can be triggered by use of any of the volatile anaesthetic agents, including methoxyflurane,<sup>10</sup> and by the depolarising neuromuscular blocking agent succinylcholine.<sup>4</sup>

## Funding

VK was funded by a Medical Research Council (UK)/British Journal of Anaesthesia Clinical Research Training Fellowship Grant (MR/N002407/1).

## Declarations of interest

PMH is an editorial board member of the *British Journal of Anaesthesia*.

## References

1. Nieuwenhuijs-Moeke GJ, Jainandunsing JS, Struys MMRF. Sevoflurane, a sigh of relief in COVID-19? *Br J Anaesth* 2020; **125**: 118–21
2. Schuster F, Moegele S, Johannsen S, Roewer N. Malignant hyperthermia in the intensive care setting. *Crit Care* 2014; **18**: 411
3. Kaura V, Aboelsaod EM, Hopkins PM. Has malignant hyperthermia really disappeared with halothane? *Br J Anaesth* 2018; **121**: 980–1
4. Gupta PK, Hopkins PM. Diagnosis and management of malignant hyperthermia. *BJA Educ* 2017; **17**: 249–54
5. Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med* 2020; **8**: 506–17
6. Glahn KPE, Bendixen D, Girard T, et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. *Br J Anaesth* 2020; **125**: 133–40
7. Bilmen JG, Hopkins PM. The use of charcoal filters in malignant hyperthermia: have they found their place? *Anaesthesia* 2019; **74**: 13–6
8. Biesecker LG, Dirksen RT, Girard T, et al. Genomic screening for malignant hyperthermia susceptibility. *Anesthesiology*. Advance online publication; 2020. <https://doi.org/10.1097/ALN.0000000000003547>
9. Shaw MA, Hopkins PM. Mission impossible or mission futile? Estimating penetrance for malignant hyperthermia. *Anesthesiology* 2019; **131**: 957–9
10. Jephcott C, Grummet J, Nguyen N, Spruyt O. A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures. *Br J Anaesth* 2018; **120**: 1040–8

doi: 10.1016/j.bja.2020.09.012

Advance Access Publication Date: 16 September 2020

© 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

# Neuraxial anaesthesia in the context of bacterial meningitis and COVID-19

Matthew B. Allen<sup>1,\*</sup>, Joseph M. Neal<sup>2</sup> and Kamen Vlassakov<sup>1</sup>

<sup>1</sup>Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA, USA and

<sup>2</sup>Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA, USA

\*Corresponding author. E-mail: [mallen13@partners.org](mailto:mallen13@partners.org)

**Keywords:** COVID-19; meningitis; neuraxial anaesthesia; regional anaesthesia; SARS-CoV-2; spinal anaesthesia

Editor—Recommendations to limit airway instrumentation and mechanical ventilation in coronavirus disease 2019 (COVID-19)

patients suggest an expanded role for regional anaesthesia.<sup>1,2</sup> The complex considerations stemming from the COVID-19

pandemic justify reconsideration of contraindications to regional anaesthesia in certain patients.<sup>2</sup> We describe use of spinal anaesthesia in a COVID-19 patient with bacteraemia, epidural infection, and bacterial meningitis. The patient provided written consent for publication of this case report.

A 64-yr-old male with history of smoking, obesity (body mass index  $38 \text{ kg m}^{-2}$ ), and bilateral total knee arthroplasties presented with left knee pain, fever, cough, lumbar radiculopathy, and urinary retention. He was haemodynamically stable with a temperature of  $38.9^\circ\text{C}$ , tachycardia, tachypnoea and  $\text{SpO}_2$  95% on room air. Physical exam showed a hot swollen left knee.

Nasopharyngeal swab testing was positive for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2), and laboratory studies showed leucocyte count  $13.9 \times 10^9 \text{ L}^{-1}$ , platelet count  $255 \times 10^9 \text{ L}^{-1}$ , and high sensitivity C-reactive protein  $>300 \text{ mg L}^{-1}$ . Knee aspiration yielded 110 ml of fluid with 3+ Gram-positive cocci in pairs. Joint aspirate and blood cultures grew methicillin-susceptible *Staphylococcus aureus* (MSSA) and i.v. vancomycin was initiated. Chest radiography was unremarkable. MRI showed diffuse conus pial and cauda equina enhancement with an epidural collection centred at the T12–T1 level tracking superiorly. This was managed non-surgically. Lumbar puncture by the neurologist yielded 16 ml of turbid, free-flowing CSF with 1+ Gram-positive cocci in pairs, and culture grew MSSA. After patient-inclusive discussion of anaesthetic options, left knee arthrotomy, drainage, and liner exchange under spinal anaesthesia was planned. The patient demonstrated an understanding of the risks and benefits, endorsed a preference for neuraxial anaesthesia, and gave informed consent.

In the operating room, levofloxacin i.v. was administered as additional antimicrobial prophylaxis. A 17G Tuohy needle was sterilely introduced at the L3–4 interspace. Flow of straw-coloured CSF was obtained at a depth of 9 cm and a multiport catheter was threaded to 14 cm to facilitate titration of local anaesthetic. Mepivacaine 1.5%, 5 ml was incrementally injected, titrated to resolution of pain and complete sensorimotor block of the lower extremities, resulting in a T8 sensory level. He remained haemodynamically stable. The 90-min surgery was uncomplicated with minimal blood loss. The patient wore a surgical mask and received oxygen  $2 \text{ L min}^{-1}$  via a nasal cannula to maintain  $\text{SpO}_2 > 92\%$ . The spinal catheter was removed at the end of the procedure. Postoperatively, he experienced no post-dural puncture headache or other complications.

Neuraxial anaesthesia is contraindicated in patients with bacteraemia, epidural abscess, or meningitis.<sup>3</sup> Neuraxial anaesthesia in infected patients should not be considered routine, but this case demonstrates a justifiable exception based on analysis of risks and benefits and competing interests. As noted in a recent editorial, 'It is reasonable to consider administering regional anaesthesia to patients at higher risk of complications simply to avoid general anaesthesia during the pandemic.'<sup>2</sup>

In COVID-19, concerns surrounding general anaesthesia include risks to staff (viral transmission) and to the patient (precipitating respiratory failure).<sup>4–6</sup> Patient safety was our paramount concern. History of obesity, smoking, and viral respiratory infection increased this patient's risk for pulmonary complications. Moreover, deleterious effects of general anaesthesia and mechanical ventilation could be exacerbated in the

setting of COVID-19 given its unpredictable and potentially lethal course.<sup>5,6</sup>

Concerns regarding neuraxial anaesthesia were considered. Because the blood, epidural space, and CSF were already infected, additional harm from repeat dural puncture was thought to be justifiably low. Intrathecal and meningeal inflammation raised theoretical uncertainties regarding efficacy and duration of spinal anaesthesia.<sup>7</sup> We administered mepivacaine because of its low pKa and threaded an intrathecal catheter to facilitate titration to effect. Preparations were made to convert to general anaesthesia and secure the airway if necessary.<sup>8</sup>

Alternative regional anaesthesia techniques were discussed with the surgical team and the patient. Peripheral nerve blocks were deemed inferior because of (1) challenges with positioning and ultrasound visualisation related to the patient's obesity and inability to tolerate lower extremity manipulation, (2) need for multiple blocks requiring nearly maximal doses of local anaesthetic, (3) slower onset, and (4) less predictable extent of sensory and motor blockade deemed essential by the surgical team. Efficacy of epidural, combined spinal–epidural, or single-shot spinal anaesthesia was considered unpredictable because of epidural and intrathecal infection. Given these variables, intrathecal titration of local anaesthetic appeared to optimise chances of success.

## Declarations of interest

The authors declare that they have no conflicts of interest.

## References

1. Uppal V, Sondekoppam R, Lobo C, et al. Practice recommendations on neuraxial anesthesia and peripheral nerve blocks during the COVID-19 pandemic. A joint statement by the American Society of Regional Anesthesia and Pain Medicine (ASRA) and European Society of Regional Anesthesia and Pain Therapy (ESRA). Available from: [https://www.asra.com/content/documents/ra-covid19\\_final.pdf](https://www.asra.com/content/documents/ra-covid19_final.pdf) (accessed 3 October 2020).
2. Macfarlane AJR, Harrop-Griffiths W, Pawa A. Regional anaesthesia and COVID-19: first choice at last? 2020;125: 243–7
3. American Society of Anesthesiologists Task Force on infectious complications associated with neuraxial techniques: practice advisory for the prevention, diagnosis, and management of infectious complications associated with neuraxial techniques: a report by the American Society of Anesthesiologists Task Force on infectious complications associated with neuraxial techniques. *Anesthesiology* 2010; 112: 530–45
4. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. *PLoS One* 2012; 7, e35797
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054–62 [published correction appears in *Lancet* 2020; 395: 1038] [published correction appears in *Lancet* 2020; 395: 1038]

6. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. *Lancet* 2020; **396**: 27–38 [published correction appears in *Lancet* 2020 Jun 9]
7. Lirk P, Hollmann MW, Strichartz G. The science of local anesthesia: basic research, clinical application, and future directions. *Anesth Analg* 2018; **126**: 1381–92
8. Chen X, Liu Y, Gong Y, et al. Perioperative management of patients infected with the novel coronavirus: recommendation from the joint task force of the Chinese society of anesthesiology and the Chinese association of anesthesiologists. *Anesthesiology* 2020; **132**: 1307–16 [published correction appears in *Anesthesiology* 2020; **133**: 693]

doi: [10.1016/j.bja.2020.09.008](https://doi.org/10.1016/j.bja.2020.09.008)

Advance Access Publication Date: 9 September 2020

© 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.